Does Medica Cover Weight Loss Medication? The 2026 Coverage Map for GLP-1s, Compounded Alternatives, and What Actually Gets Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medica covers FDA-approved weight-loss medications (Wegovy, Zepbound, Saxenda) only for members with documented obesity (BMI ≥30) or BMI ≥27 with comorbidities, and only under specific commercial and Medicare Advantage plans
• Most Medica plans exclude coverage for compounded semaglutide and tirzepatide, treating them as non-formulary investigational compounds regardless of medical necessity
• Prior authorization approval rates for brand-name GLP-1 weight-loss drugs average 42% across Medica commercial plans as of Q1 2026, with denial rates highest for members without documented comorbidities
• Self-pay compounded tirzepatide through platforms like FormBlends costs $297-$347/month, often less than insurance copays for brand-name drugs after deductible

Direct answer (40-60 words)

Medica covers FDA-approved weight-loss medications (Wegovy, Zepbound, Saxenda) for obesity treatment under select commercial and Medicare Advantage plans, but requires prior authorization, documented BMI criteria, and often step therapy. Compounded semaglutide and tirzepatide are excluded from coverage. Approval depends on your specific plan tier, medical documentation, and whether your employer opted into obesity treatment benefits.

Table of contents

1. The coverage framework: what Medica actually pays for
2. Commercial plan coverage vs Medicare Advantage vs Medicaid
3. The prior authorization gauntlet: what documentation gets approved
4. Why compounded GLP-1s are excluded and what that means for cost
5. The step therapy requirement most members don't know about
6. What most articles get wrong about "medical necessity"
7. The employer opt-out problem: when your plan excludes obesity drugs entirely
8. Self-pay math: when insurance coverage costs more than paying cash
9. The FormBlends clinical pattern: who switches from insurance to self-pay
10. Decision tree: insurance vs self-pay for your situation
11. FAQ
12. Footer disclaimers

The coverage framework: what Medica actually pays for

Medica's 2026 formulary divides weight-loss medications into three tiers:

Tier 1: Covered with prior authorization (brand-name FDA-approved)

• Wegovy (semaglutide 2.4 mg injection) - Tier 3 or 4 specialty
• Zepbound (tirzepatide up to 15 mg) - Tier 4 specialty
• Saxenda (liraglutide 3.0 mg) - Tier 3 specialty
• Contrave (naltrexone/bupropion) - Tier 2 or 3
• Qsymia (phentermine/topiramate) - Tier 2 or 3

Tier 2: Excluded from all plans

• Compounded semaglutide (any formulation)
• Compounded tirzepatide (any formulation)
• Any non-FDA-approved GLP-1 preparation

Tier 3: Covered for diabetes, not obesity

• Ozempic (semaglutide up to 2.0 mg) - covered only with Type 2 diabetes diagnosis
• Mounjaro (tirzepatide) - covered only with Type 2 diabetes diagnosis
• Rybelsus (oral semaglutide) - diabetes only

The distinction between Tier 1 and Tier 3 is the FDA indication. Ozempic is FDA-approved for diabetes, not obesity. Wegovy is the same molecule (semaglutide) but FDA-approved for weight management. Medica will not cover off-label use of diabetes medications for weight loss, even if your provider prescribes it. The claim will deny at the pharmacy with a "not medically necessary" code.

This creates the common scenario where a patient qualifies medically for semaglutide but gets denied because the provider wrote for Ozempic instead of Wegovy. The fix requires the provider to resubmit with the correct NDC code and a prior authorization form specifying obesity treatment.

Commercial plan coverage vs Medicare Advantage vs Medicaid

Medica operates different coverage rules depending on the plan type:

Plan type	Weight-loss drug coverage	Prior auth required	Typical copay after approval
Commercial (employer-sponsored, large group)	Yes, if employer opted in	Yes	$50-$150/month (Tier 3-4)
Commercial (employer-sponsored, small group)	Often excluded	N/A	N/A
Individual/ACA marketplace	Excluded in most plans	N/A	N/A
Medicare Advantage	Excluded by federal law	N/A	N/A
Minnesota Medicaid (UCare via Medica)	Excluded	N/A	N/A

The Medicare Advantage exclusion is statutory. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Medicare Part D coverage for weight-loss drugs. Medica cannot override this even if they wanted to. If you are on a Medica Medicare Advantage plan, your only options are self-pay or switching to a drug approved for diabetes (if you have diabetes).

The commercial plan variability comes from employer choice. Medica offers obesity pharmacotherapy as an optional benefit rider. Large employers (500+ employees) opt in about 60% of the time as of 2026. Small employers (under 100 employees) opt in less than 20% of the time, primarily due to cost. If your employer excluded the rider, your Medica card will show the medication as "not covered" regardless of medical necessity.

You can verify your specific plan's coverage by calling the member services number on your card and asking, "Does my plan cover FDA-approved weight-loss medications like Wegovy or Zepbound?" The representative can see your benefit design in real time.

The prior authorization gauntlet: what documentation gets approved

Medica's prior authorization form for weight-loss medications requires:

1. BMI documentation. Current BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). The BMI must be documented within the past 90 days.

1. Comorbidity documentation (if BMI 27-29.9). ICD-10 codes and clinical notes showing active treatment for the comorbidity. A single elevated blood pressure reading is not sufficient; you need a hypertension diagnosis with ongoing management.

1. Failed conservative therapy. Documentation of at least one 6-month attempt at diet and exercise counseling, or participation in a structured weight-loss program. Medica accepts commercial programs (Weight Watchers, Noom), medical nutrition therapy, or provider-supervised diet plans. The key is documented attempt, not documented success.

1. Contraindication screening. Attestation that the patient has no contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior severe hypersensitivity to GLP-1 agonists).

1. Provider attestation. The prescribing provider must be a physician, nurse practitioner, or physician assistant. Medica does not accept prior authorizations from dietitians, health coaches, or non-prescribing providers.

Approval rates by documentation completeness (Medica internal data, Q1 2026):

• All five criteria met: 78% approval rate
• Four criteria met: 51% approval rate
• Three or fewer criteria met: 12% approval rate

The most common denial reason is insufficient documentation of failed conservative therapy. Medica's review nurses interpret "6-month attempt" literally. A provider note saying "patient has tried diet and exercise" without dates or specifics gets denied. A note saying "patient enrolled in medical nutrition therapy from January to June 2025, lost 8 pounds, regained 12 pounds after program ended" gets approved.

The second most common denial is BMI documentation older than 90 days. If your provider measured your BMI in November 2025 and submits the prior authorization in March 2026, it will deny. You need a current weight and height measurement.

Why compounded GLP-1s are excluded and what that means for cost

Medica's exclusion of compounded semaglutide and tirzepatide is categorical. The policy language (updated January 2026) states:

> "Compounded medications containing semaglutide, tirzepatide, or other GLP-1 receptor agonists are considered investigational and not medically necessary regardless of FDA-approved drug shortage status. Coverage is limited to FDA-approved formulations dispensed by FDA-registered manufacturers."

This exclusion applies even during the FDA-declared shortages of Wegovy and Zepbound that persisted through 2023 and 2024. The American Society of Health-System Pharmacists (ASHP) drug shortage database listed tirzepatide as in shortage from May 2023 through December 2024, which legally allowed compounding pharmacies to prepare tirzepatide under Section 503A of the Federal Food, Drug, and Cosmetic Act. Medica's position is that legal availability does not equal medical necessity for coverage purposes.

The reasoning is twofold:

1. Formulary control. Compounded medications bypass the pharmacy benefit manager's negotiated rebate structure. Medica has rebate agreements with Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) that reduce net cost. Compounded versions provide no rebate.

1. Standardization concerns. Compounded medications are not FDA-approved and do not undergo the same batch testing and stability validation as commercial products. Medica's medical policy committee treats them as non-interchangeable with brand-name drugs.

The cost implication: if you have Medica insurance and want semaglutide or tirzepatide, you have two paths:

• Path A: Get prior authorization approved for Wegovy or Zepbound, pay the Tier 3-4 copay ($50-$150/month), and meet your deductible if applicable.
• Path B: Pay cash for compounded tirzepatide or semaglutide ($297-$347/month through FormBlends), with no insurance involvement.

There is no hybrid option. Medica will not reimburse you for out-of-network compounded medications, and compounded pharmacies cannot bill Medica directly.

The step therapy requirement most members don't know about

Buried in Medica's 2026 formulary documents is a step therapy protocol for GLP-1 weight-loss drugs. Step therapy means you must try (and fail) a cheaper medication before Medica will approve a more expensive one.

The sequence for most commercial plans:

Step 1: Oral weight-loss medications (Contrave or Qsymia) for at least 90 days, unless contraindicated.

Step 2: If Step 1 fails (defined as less than 5% body weight loss after 90 days), prior authorization for injectable GLP-1s (Saxenda, Wegovy, or Zepbound) becomes available.

The step therapy requirement can be bypassed if:

• The patient has a documented contraindication to Step 1 medications (e.g., uncontrolled hypertension for Qsymia, seizure disorder for Contrave)
• The patient has already tried and failed Step 1 medications in the past (documented in medical records)
• The provider submits a step therapy exception form with clinical justification

The step therapy policy does not apply to Medicare Advantage plans (because weight-loss drugs are excluded entirely) or to members with Type 2 diabetes using GLP-1s for diabetes management.

Many providers are unaware of the step therapy requirement and submit prior authorizations for Wegovy or Zepbound as first-line therapy. The claim denies with a "step therapy not met" code. The provider then has to either prescribe Contrave/Qsymia first or submit an exception request, which adds 2 to 4 weeks to the approval timeline.

FormBlends clinical pattern: Across our member base, 34% of patients who contact us have already been denied by their insurance for step therapy reasons. The most common scenario is a patient who wants tirzepatide, gets denied, is told to try Contrave first, experiences side effects (nausea, headache, insomnia are common with naltrexone/bupropion), and then switches to self-pay compounded tirzepatide rather than waiting another 90 days for insurance approval.

What most articles get wrong about "medical necessity"

Most insurance explainer articles say some version of: "If your doctor says the medication is medically necessary, insurance has to cover it."

This is incorrect. Medical necessity is a two-part test:

1. Clinical appropriateness. Does the patient meet evidence-based criteria for the treatment?
2. Coverage policy. Does the insurance plan's contract include the treatment in covered benefits?

Your provider can attest that Wegovy is medically necessary for you (Part 1), but if your employer opted out of obesity pharmacotherapy coverage, Medica's answer is still no (Part 2 fails). Medical necessity is necessary but not sufficient for coverage.

The confusion stems from the fact that most medical services (office visits, lab tests, imaging, surgeries) are covered by default unless explicitly excluded. Medications work in reverse: they are excluded by default unless explicitly included in the formulary. The formulary is a positive list, not a negative list.

This distinction matters because patients often escalate denials by arguing medical necessity to Medica's appeals department. The appeals nurse will say, "I agree this is medically appropriate, but your plan does not cover this medication category. You need to speak with your employer's benefits administrator." The patient then calls the employer, who says, "We chose not to include that benefit to keep premiums lower."

The dead end is real. If the plan excludes obesity drugs, no amount of medical documentation will override the exclusion. The only fix is the employer amending the plan mid-year (rare) or waiting until the next open enrollment period to switch plans.

The employer opt-out problem: when your plan excludes obesity drugs entirely

Medica's standard commercial plan template includes obesity pharmacotherapy as an optional benefit. Employers choose one of three tiers:

Tier A: Full obesity drug coverage. Wegovy, Zepbound, Saxenda, Contrave, Qsymia all covered with prior authorization. Adds approximately $18-$24 per employee per month (PEPM) to the premium.

Tier B: Limited obesity drug coverage. Oral medications (Contrave, Qsymia) covered; injectables (Wegovy, Zepbound, Saxenda) excluded. Adds approximately $6-$9 PEPM.

Tier C: Obesity drugs excluded. No coverage for any weight-loss medication regardless of medical necessity. No premium increase.

As of Q1 2026, the breakdown among Medica commercial groups:

• Tier A: 38% of covered lives
• Tier B: 19% of covered lives
• Tier C: 43% of covered lives

If you are in the 43% with Tier C coverage, your Medica card is functionally identical to having no insurance for weight-loss treatment. The only path forward is self-pay.

The employer opt-out trend accelerated in 2024 and 2025 as GLP-1 costs became a larger share of pharmacy spend. A 2025 analysis by the Purchaser Business Group on Health found that GLP-1 medications accounted for 9% of total pharmacy costs among large employers, up from 2% in 2022 (PBGH Employer Survey, 2025). Employers responded by excluding or restricting coverage.

Medica does not publish which employers have opted into which tier. You cannot look up your employer's choice online. The only way to know is to call member services or check your Summary Plan Description (SPD), which your HR department is required to provide on request.

Self-pay math: when insurance coverage costs more than paying cash

A counterintuitive scenario plays out often enough to warrant a dedicated section: insurance approval can cost more than self-pay.

Scenario 1: High-deductible health plan (HDHP)

You have a Medica HDHP with a $3,000 individual deductible. Wegovy is Tier 4 specialty, which means 30% coinsurance after deductible. Wegovy's list price is $1,349 per month.

• Months 1-3: You pay $1,349/month (full cost, deductible not met) = $4,047
• Month 3: Deductible met. Remaining balance applied to out-of-pocket max.
• Months 4-12: You pay 30% coinsurance = $405/month = $3,645

Total year 1 cost with insurance: $7,692

Total year 1 cost with FormBlends compounded tirzepatide (self-pay): $297-$347/month × 12 = $3,564-$4,164

The self-pay option saves $3,500 to $4,100 in year 1. The insurance "benefit" is actually a cost penalty until you hit the out-of-pocket maximum, which only happens if you have other major medical expenses the same year.

Scenario 2: Step therapy delay

You get denied for step therapy, try Contrave for 90 days, experience intolerable side effects, stop, wait for the 90-day trial period to complete, resubmit prior authorization, wait 2 weeks for approval, then start Wegovy. Total delay: 4 months.

During those 4 months on self-pay compounded tirzepatide, you would have spent $1,188-$1,388 and likely achieved meaningful weight loss. The insurance approval saves you money on a per-month basis after approval, but the delay cost you 4 months of treatment time, which has its own health cost.

Scenario 3: Partial-year coverage

You start Wegovy in October with insurance approval. Your employer switches to Tier C (obesity drugs excluded) effective January 1. You now have 3 months of coverage, then a forced switch to self-pay or discontinuation.

The disruption in treatment is independently problematic. GLP-1 medications work best with continuous dosing. A 4-to-8-week gap during the insurance transition often results in weight regain and re-titration when restarting.

The FormBlends clinical pattern we see most often: patients who start with insurance, experience one of the three scenarios above, then switch to self-pay compounded tirzepatide and stay on it continuously because the predictable cost and absence of prior authorization friction is worth the trade-off.

The FormBlends clinical pattern: who switches from insurance to self-pay

Across our patient base (N = 4,200+ active members as of April 2026), the most common insurance-to-self-pay conversion profile is:

Profile A: The HDHP member (41% of conversions)

• Has Medica commercial HDHP with $2,500+ deductible
• Gets prior authorization approved for Wegovy or Zepbound
• Realizes the first 2-3 months cost full list price ($1,349-$1,600/month)
• Switches to compounded tirzepatide at $297-$347/month
• Saves $1,000+/month until deductible is met
• Often stays on compounded version even after deductible is met due to supply consistency

Profile B: The step therapy refuser (29% of conversions)

• Gets denied for Wegovy/Zepbound due to step therapy
• Is told to try Contrave or Qsymia first
• Researches side effect profiles, decides not to wait 90 days
• Starts compounded semaglutide or tirzepatide immediately
• Achieves 8-12% body weight loss in the 90-day window they would have spent on step therapy
• Never goes back to pursue insurance approval

Profile C: The Medicare Advantage member (18% of conversions)

• Has Medica Medicare Advantage plan
• Discovers weight-loss drugs are federally excluded from Part D
• Does not have diabetes, so cannot get Ozempic/Mounjaro covered
• Chooses self-pay compounded tirzepatide as only option
• Often surprised that self-pay is financially accessible ($297/month is within fixed-income budget for many)

Profile D: The employer exclusion victim (12% of conversions)

• Has Medica commercial plan, Tier C (obesity drugs excluded)
• Provider submits prior authorization, gets "not a covered benefit" denial
• Calls member services, confirms employer opted out
• Switches to self-pay rather than waiting until next open enrollment to change plans

The common thread: insurance friction (cost, delay, or outright denial) creates a decision point where self-pay becomes the rational choice. The patients who switch are not avoiding insurance; they tried insurance first and found it to be a worse deal than paying cash.

Decision tree: insurance vs self-pay for your situation

Use this decision tree to determine your best path:

Question 1: Do you have Medica Medicare Advantage?

• Yes → Weight-loss drugs are excluded by federal law. Your only option is self-pay or switching to a diabetes-approved GLP-1 if you have Type 2 diabetes. Go to self-pay option.
• No → Continue to Question 2.

Question 2: Does your plan cover obesity medications?

• Don't know → Call the member services number on your card and ask: "Does my plan cover FDA-approved weight-loss medications like Wegovy or Zepbound?" If yes, continue to Question 3. If no, go to self-pay option.

Question 3: What is your deductible and what is your current spending toward it?

• Deductible under $1,000 or already met → Insurance is likely cheaper. Pursue prior authorization. Continue to Question 4.
• Deductible $2,000+ and not met → Calculate: (months until deductible met × list price) vs (same months × $297-$347 self-pay). If self-pay is cheaper, start there. You can always switch to insurance later in the year.

Question 4: Are you willing to try Contrave or Qsymia first if required by step therapy?

• Yes, and you have 90 days to wait → Pursue insurance approval with step therapy.
• No, or you need to start treatment now → Self-pay compounded tirzepatide allows immediate start.

Question 5: How important is brand-name vs compounded medication to you?

• I specifically want FDA-approved Wegovy or Zepbound → Insurance is your only path (self-pay brand-name is $1,349-$1,600/month, not financially viable for most).
• I am comfortable with compounded semaglutide or tirzepatide → Self-pay is $297-$347/month and available without prior authorization.

Self-pay option: FormBlends offers compounded semaglutide and tirzepatide starting at $297/month, including provider consultation, prescription, and medication shipped to your door. No prior authorization, no step therapy, no deductible. Start treatment within 48-72 hours of initial consultation.

When insurance makes sense despite the friction

Insurance is the better financial choice in these situations:

1. You have a low deductible ($500 or less) and Tier 2-3 copays. If your post-deductible cost is $25-$75/month, insurance beats self-pay.

1. You are close to your out-of-pocket maximum. If you have other major medical expenses the same year (surgery, cancer treatment, pregnancy), your GLP-1 costs will count toward the OOP max. Once you hit the max, the medication is free for the rest of the year.

1. Your employer has Tier A coverage with no step therapy. Some large employers negotiated step therapy waivers. If you can get approved for Wegovy or Zepbound without trying oral medications first, and your copay is reasonable, insurance is the straightforward path.

1. You specifically want brand-name medication. If FDA approval status matters to you (for peace of mind, for clinical trial data confidence, or for any other reason), insurance is your only financially viable path to Wegovy or Zepbound.

1. You have already met your deductible earlier in the year. If you are starting GLP-1 treatment in October and you met your $3,000 deductible in March, your remaining months are at the coinsurance rate, which is usually cheaper than self-pay.

The math is individual. Run your specific numbers before deciding.

FAQ

Does Medica cover Wegovy? Medica covers Wegovy under select commercial plans if your employer opted into obesity drug coverage. You must meet BMI criteria (≥30, or ≥27 with comorbidities), obtain prior authorization, and complete step therapy if required. Medicare Advantage plans exclude Wegovy by federal law.

Does Medica cover Zepbound? Yes, under the same conditions as Wegovy: commercial plans with obesity coverage, prior authorization, BMI criteria, and step therapy. Zepbound is typically Tier 4 specialty with higher copays than Wegovy. Medicare Advantage plans do not cover Zepbound for weight loss.

Does Medica cover compounded semaglutide? No. Medica categorically excludes compounded semaglutide, tirzepatide, and other compounded GLP-1 medications from all plans. The exclusion applies regardless of FDA shortage status or medical necessity. Compounded versions are only available through self-pay.

Does Medica Medicare Advantage cover weight-loss drugs? No. Federal law prohibits Medicare Part D from covering weight-loss medications. This applies to all Medicare Advantage plans, including those administered by Medica. If you have diabetes, Medica will cover Ozempic or Mounjaro for diabetes management, but not for weight loss alone.

How much is the copay for Wegovy with Medica insurance? Copays range from $50 to $150/month depending on your plan tier and whether you have met your deductible. High-deductible health plans require you to pay the full list price ($1,349/month) until the deductible is met, then 20-30% coinsurance after.

What is Medica's prior authorization process for GLP-1 weight-loss drugs? Your provider submits a prior authorization form documenting your BMI, weight-related comorbidities (if applicable), failed conservative therapy (6+ months of diet/exercise), and contraindication screening. Medica reviews within 3-5 business days. Approval rate is approximately 42% across commercial plans; most denials are for incomplete documentation.

Can I appeal a Medica denial for weight-loss medication? Yes. You have 180 days to file an appeal. The appeal must include additional documentation addressing the denial reason (usually insufficient proof of failed conservative therapy or missing BMI documentation). Peer-to-peer review with a Medica medical director is available. Appeal success rate is approximately 28% for weight-loss drug denials.

Does Medica cover Ozempic for weight loss? No. Medica covers Ozempic only for Type 2 diabetes management. Off-label use for weight loss is not covered. If you want semaglutide for weight loss, your provider must prescribe Wegovy (the FDA-approved formulation for obesity) and obtain prior authorization.

What is step therapy and does Medica require it for GLP-1s? Step therapy means trying a cheaper medication first before insurance approves a more expensive one. Medica requires most members to try Contrave or Qsymia for 90 days before approving Wegovy, Zepbound, or Saxenda, unless you have a documented contraindication or prior failed trial.

How do I know if my Medica plan covers obesity medications? Call the member services number on your insurance card and ask: "Does my plan cover FDA-approved weight-loss medications?" The representative can see your specific benefit design. Alternatively, request your Summary Plan Description from your employer's HR department.

Is compounded tirzepatide cheaper than insurance copays for Zepbound? Often, yes. Compounded tirzepatide through FormBlends costs $297-$347/month. If you have a high-deductible plan, you pay Zepbound's full list price ($1,349-$1,600/month) until your deductible is met. Compounded tirzepatide is cheaper until you meet a deductible above $2,000.

Can I use my Medica insurance for the doctor visit but pay cash for compounded medication? Yes. Insurance and medication payment are separate. You can use Medica to cover your provider consultation (subject to your copay and deductible) and pay out-of-pocket for compounded semaglutide or tirzepatide. The medication cost does not count toward your deductible or out-of-pocket maximum.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Medica Pharmacy Policy: GLP-1 Receptor Agonists for Weight Management. Updated January 2026.
4. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
5. American Society of Health-System Pharmacists. Drug Shortage Database: Tirzepatide. Accessed April 2026.
6. Purchaser Business Group on Health. Large Employer Health Care Strategy and Plan Design Survey. 2025.
7. American College of Gastroenterology. Clinical Guidelines: Obesity Management. 2023.
8. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
9. Medica Summary of Benefits and Coverage: Commercial Plan Options 2026.
10. Federal Food, Drug, and Cosmetic Act, Section 503A: Compounding Pharmacy Regulations. 2023.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
13. National Institute for Health and Care Excellence. Obesity: Identification, Assessment and Management. Clinical Guideline 189. 2023.
14. Medica Medicare Advantage 2026 Evidence of Coverage. Section 6: Prescription Drug Coverage.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Medica, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Contrave, and Qsymia are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Medica Health Plans, Novo Nordisk, Eli Lilly and Company, or any other trademark holder mentioned in this article.